In-Hospital Outcomes of Chronic Total Occlusion Percutaneous Coronary Interventions in Patients With Prior Coronary Artery Bypass Graft Surgery.


Journal

Circulation. Cardiovascular interventions
ISSN: 1941-7632
Titre abrégé: Circ Cardiovasc Interv
Pays: United States
ID NLM: 101499602

Informations de publication

Date de publication:
03 2019
Historique:
entrez: 16 3 2019
pubmed: 16 3 2019
medline: 24 3 2020
Statut: ppublish

Résumé

We examined the procedural outcomes of chronic total occlusions (CTO) percutaneous coronary interventions in patients with prior coronary artery bypass graft surgery (CABG). We compared the clinical, angiographic characteristics and outcomes of 3486 CTO interventions performed in patients with (n=1101) and without (n=2317) prior CABG at 21 centers. Prior CABG patients (32% of total cohort) were older (67±9 versus 63±10 years; P<0.001) and had more comorbidities and lower left ventricular ejection fraction (50% [40-58] versus 55% [45-60]; P<0.001). The CTO target vessel in prior CABG patients was the right coronary artery (56%), circumflex (26%), and left anterior descending artery (17%). The mean J-CTO (2.9±1.2 versus 2.2±1.3; P<0.001) and PROGRESS-CTO (Prospective Global Registry for the Study of Chronic Total Occlusion Intervention; 1.5±1.1 versus 1.2±1.0; P<0.001) score was higher in prior CABG patients. Retrograde (53% versus 30%, P<0.001) and antegrade dissection reentry (35% versus 28%; P<0.001) techniques were used more frequently in prior CABG patients. Prior CABG patients had lower technical (84% versus 89%; P<0.001) and procedural (82% versus 87%, P<0.001) success, but similar incidence of in-hospital major complications (3.1% versus 2.5%; P=0.287). In-hospital mortality (1% versus 0.4%; P=0.016) and coronary perforation (7.1% versus 3.1%; P<0.001) occurred more frequently in prior CABG patients, however, CABG patients had a lower incidence of pericardial tamponade (0.1% versus 1.0%; P=0.002) and pericardiocentesis (0% versus 1.3%; P<0.001). In a large multicenter CTO percutaneous coronary interventions registry, prior CABG patients had lower success rate but similar overall risk for complications, although mortality was higher and the incidence of tamponade was lower. URL: https://www.clinicaltrials.gov . Unique identifier: NCT02061436.

Sections du résumé

BACKGROUND
We examined the procedural outcomes of chronic total occlusions (CTO) percutaneous coronary interventions in patients with prior coronary artery bypass graft surgery (CABG).
METHODS AND RESULTS
We compared the clinical, angiographic characteristics and outcomes of 3486 CTO interventions performed in patients with (n=1101) and without (n=2317) prior CABG at 21 centers. Prior CABG patients (32% of total cohort) were older (67±9 versus 63±10 years; P<0.001) and had more comorbidities and lower left ventricular ejection fraction (50% [40-58] versus 55% [45-60]; P<0.001). The CTO target vessel in prior CABG patients was the right coronary artery (56%), circumflex (26%), and left anterior descending artery (17%). The mean J-CTO (2.9±1.2 versus 2.2±1.3; P<0.001) and PROGRESS-CTO (Prospective Global Registry for the Study of Chronic Total Occlusion Intervention; 1.5±1.1 versus 1.2±1.0; P<0.001) score was higher in prior CABG patients. Retrograde (53% versus 30%, P<0.001) and antegrade dissection reentry (35% versus 28%; P<0.001) techniques were used more frequently in prior CABG patients. Prior CABG patients had lower technical (84% versus 89%; P<0.001) and procedural (82% versus 87%, P<0.001) success, but similar incidence of in-hospital major complications (3.1% versus 2.5%; P=0.287). In-hospital mortality (1% versus 0.4%; P=0.016) and coronary perforation (7.1% versus 3.1%; P<0.001) occurred more frequently in prior CABG patients, however, CABG patients had a lower incidence of pericardial tamponade (0.1% versus 1.0%; P=0.002) and pericardiocentesis (0% versus 1.3%; P<0.001).
CONCLUSIONS
In a large multicenter CTO percutaneous coronary interventions registry, prior CABG patients had lower success rate but similar overall risk for complications, although mortality was higher and the incidence of tamponade was lower.
CLINICAL TRIAL REGISTRATION
URL: https://www.clinicaltrials.gov . Unique identifier: NCT02061436.

Identifiants

pubmed: 30871357
doi: 10.1161/CIRCINTERVENTIONS.118.007338
doi:

Banques de données

ClinicalTrials.gov
['NCT02061436']

Types de publication

Comparative Study Journal Article Multicenter Study Observational Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e007338

Auteurs

Peter Tajti (P)

Minneapolis Heart Institute and Minneapolis Heart Institute Foundation, Abbott Northwestern Hospital, MN (P.T., M.N.B., I.X., L.I.S., B.V.R., E.S.B.).
Division of Invasive Cardiology, Second Department of Internal Medicine and Cardiology Center, University of Szeged, Hungary (P.T., I.U.).

Dimitri Karmpaliotis (D)

Columbia University, New York, NY (D.K., J.W.M., N.J.L., M.P., A.J.K., Z.A.A., D.D.).

Khaldoon Alaswad (K)

Henry Ford Hospital, Detroit, MI (K.A.).

Farouc A Jaffer (FA)

Massachusetts General Hospital, Boston (F.A.J.).

Robert W Yeh (RW)

Beth Israel Deaconess Medical Center, Boston, MA (R.W.Y.).

Mitul Patel (M)

VA San Diego Healthcare System and University of California San Diego, La Jolla (M.P., E.M.).

Ehtisham Mahmud (E)

VA San Diego Healthcare System and University of California San Diego, La Jolla (M.P., E.M.).

James W Choi (JW)

Baylor Heart and Vascular Hospital, Dallas, TX (J.W.C.).

M Nicholas Burke (MN)

Minneapolis Heart Institute and Minneapolis Heart Institute Foundation, Abbott Northwestern Hospital, MN (P.T., M.N.B., I.X., L.I.S., B.V.R., E.S.B.).

Anthony H Doing (AH)

Medical Center of the Rockies, Loveland, CO (A.H.D., P.D.).

Phil Dattilo (P)

Medical Center of the Rockies, Loveland, CO (A.H.D., P.D.).

Catalin Toma (C)

University of Pittsburgh Medical Center, PA (C.T., A.J.C.S.).

A J Conrad Smith (AJC)

University of Pittsburgh Medical Center, PA (C.T., A.J.C.S.).

Barry Uretsky (B)

VA Central Arkansas Healthcare System, Little Rock (B.U.).

Elizabeth Holper (E)

The Heart Hospital Baylor Plano, TX (E.H., S.P.).

Srinivas Potluri (S)

The Heart Hospital Baylor Plano, TX (E.H., S.P.).

R Michael Wyman (RM)

Torrance Memorial Medical Center, CA (R.M.W.).

David E Kandzari (DE)

Piedmont Heart Institute, Atlanta, GA (D.E.K.).

Santiago Garcia (S)

VA Minneapolis Healthcare System and University of Minnesota (S.G.).

Oleg Krestyaninov (O)

Meshalkin Siberian Federal Biomedical Research Center, Ministry of Health of Russian Federation, Novosibirsk (O.K., D.K.).

Dmitrii Khelimskii (D)

Meshalkin Siberian Federal Biomedical Research Center, Ministry of Health of Russian Federation, Novosibirsk (O.K., D.K.).

Michalis Koutouzis (M)

Korgialeneio-Benakeio Hellenic Red Cross General Hospital of Athens, Greece (M.K., I.T.).

Ioannis Tsiafoutis (I)

Korgialeneio-Benakeio Hellenic Red Cross General Hospital of Athens, Greece (M.K., I.T.).

Wissam Jaber (W)

Emory University, Atlanta, GA (W.J., H.S.).

Habib Samady (H)

Emory University, Atlanta, GA (W.J., H.S.).

Jeffrey W Moses (JW)

Columbia University, New York, NY (D.K., J.W.M., N.J.L., M.P., A.J.K., Z.A.A., D.D.).

Nicholas J Lembo (NJ)

Columbia University, New York, NY (D.K., J.W.M., N.J.L., M.P., A.J.K., Z.A.A., D.D.).

Manish Parikh (M)

Columbia University, New York, NY (D.K., J.W.M., N.J.L., M.P., A.J.K., Z.A.A., D.D.).

Ajay J Kirtane (AJ)

Columbia University, New York, NY (D.K., J.W.M., N.J.L., M.P., A.J.K., Z.A.A., D.D.).

Ziad A Ali (ZA)

Columbia University, New York, NY (D.K., J.W.M., N.J.L., M.P., A.J.K., Z.A.A., D.D.).

Darshan Doshi (D)

Columbia University, New York, NY (D.K., J.W.M., N.J.L., M.P., A.J.K., Z.A.A., D.D.).

Iosif Xenogiannis (I)

Minneapolis Heart Institute and Minneapolis Heart Institute Foundation, Abbott Northwestern Hospital, MN (P.T., M.N.B., I.X., L.I.S., B.V.R., E.S.B.).

Larissa I Stanberry (LI)

Minneapolis Heart Institute and Minneapolis Heart Institute Foundation, Abbott Northwestern Hospital, MN (P.T., M.N.B., I.X., L.I.S., B.V.R., E.S.B.).

Bavana V Rangan (BV)

Minneapolis Heart Institute and Minneapolis Heart Institute Foundation, Abbott Northwestern Hospital, MN (P.T., M.N.B., I.X., L.I.S., B.V.R., E.S.B.).

Imre Ungi (I)

Division of Invasive Cardiology, Second Department of Internal Medicine and Cardiology Center, University of Szeged, Hungary (P.T., I.U.).

Subhash Banerjee (S)

VA North Texas Health Care System and University of Texas Southwestern Medical Center, Dallas (S.B., E.S.B.).

Emmanouil S Brilakis (ES)

Minneapolis Heart Institute and Minneapolis Heart Institute Foundation, Abbott Northwestern Hospital, MN (P.T., M.N.B., I.X., L.I.S., B.V.R., E.S.B.).
VA North Texas Health Care System and University of Texas Southwestern Medical Center, Dallas (S.B., E.S.B.).

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH